Tag:
CAD106
Latest Headlines
Latest Headlines
Cytos Biotechnology soars on results of asthma-drug study
After closing out a failed Novartis partnership in January, Cytos Biotechnology has registered some upbeat data from a mid-stage study of its lead drug against allergic asthma. On the news, Zurich-based Cytos' shares jumped 14% as of early this morning, Bloomberg reported.
Novartis, Cytos Alzheimer's vax shows immune response
CAD106, a vaccine co-developed by Novartis and Cytos that targets the amyloid β peptide, has shown early hints of immune responses in a clinical trial in people with Alzheimer's disease. This vaccine could have potential to slow the development of the disease.
